Ascendis Pharma A/S
corporate_fare Company Profile
Ascendis Pharma A/S (NASDAQ:ASND) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 32 items for ASND at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-10, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 16 rated 8 or above. Recent SEC coverage for ASND spans 6-K, 4.
Recent high-impact activity:
- Ascendis Pharma's TransCon CNP Shows Significant Benefits in Infants with Achondroplasia, Preventing Surgeries
- Ascendis Reports Positive Week 52 Infant Data for TransCon CNP in Achondroplasia
- Ascendis Settles YUVIWEL Litigation with BioMarin — 20% U.S. Royalty Through 2030
- Ascendis Settles YUVIWEL Litigation with BioMarin, Secures Global License
- Ascendis' Eyconis Starts First Human Trial for Wet AMD Drug EYC-0305
Financial Snapshot
Dilution Risk
Low riskFiling-implied dilution signals for ASND, detected from its recent SEC filings · based on capital-structure filings through 2026-04-21.
Redemption of Convertible Notes · Triggered by Strong Stock Performance
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
ASND files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.